Leone M, Attanasio A, Grazzi L, Libro G, D'Amico D, Moschiano F, Bussone G
Headache Center, Istituto Neurologico Carlo Besta, Milano, Italy.
Headache. 1997 Oct;37(9):559-60. doi: 10.1046/j.1526-4610.1997.3709559.x.
Transdermal clonidine has recently been reported to be efficacious in the prophylaxis of cluster headache. A 2-week course of transdermal clonidine (5 mg the first week, 7.5 mg the second week) preceded by a 5-day run-in period, was administered to 16 patients with episodic cluster headache in an active cluster period. In 5 patients, the painful attacks disappeared after the seventh day of treatment. For the group as a whole, no significant variations in headache frequency, pain intensity, or attack duration were observed between the run-in period and the first and second weeks of treatment (ANOVA). Further studies are necessary to clarify the effectiveness of transdermal clonidine in the prophylaxis of episodic cluster headache.
最近有报道称,透皮可乐定在预防丛集性头痛方面有效。在16例处于发作期的发作性丛集性头痛患者中,先进行了为期5天的导入期,然后给予为期2周的透皮可乐定疗程(第一周5毫克,第二周7.5毫克)。5例患者在治疗第7天后疼痛发作消失。对于整个组而言,在导入期与治疗的第一周和第二周之间,未观察到头痛频率、疼痛强度或发作持续时间有显著变化(方差分析)。需要进一步研究以阐明透皮可乐定在预防发作性丛集性头痛方面的有效性。